Novartis announced significant clinical successes for its monoclonal antibody ianalumab, which demonstrated efficacy in Phase III trials for Sjögren’s disease and primary immune thrombocytopenia (ITP). The trials showed statistically significant improvements in disease activity reduction and maintenance of platelet levels, respectively. Ianalumab’s dual mechanism involves B-cell depletion and BAFF receptor inhibition, positioning it as a promising therapy in autoimmune conditions lacking effective treatments in the U.S. These outcomes could pave the way for new therapeutic indications for Novartis.